Drug Channels

SEPTEMBER 7, 2022

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. will face multiple biosimilar competitors. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Prices are dropping while adoption accelerates.

Biosimilars 98

Biosimilars Marketing Production Drugs 98

Drug Discovery World

SEPTEMBER 2, 2022

The Tech Theatre, supported by DDW, at ELRIG Drug Discovery 2022 will feature a series of seminars focused on automation and technology for drug discovery. . How can automation push the development of biologics and biosimilars? . The remote lab: Is this the future? . Click here ? now to register. .

Biosimilars 130

Biosimilars Drugs Science Production 130

Drug Channels

JANUARY 10, 2023

Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. I also note some troubling research on the patient impact of exclusions—although much remains unknown.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Channels

AUGUST 23, 2022

on key specialty pharmacy trends Evidence for biosimilar-to-biosimilar switching Plus, Dr. Glaucomflecken takes on PBMs! Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. P.S. Join my more than 31,000 LinkedIn followers for daily links to neat stuff. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Specialty Pharmacies Pharmacy Drugs 98

Drug Channels

DECEMBER 12, 2022

Click here to see the original post and comments from September 2022. By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharmacy Hospitals Marketing 98

Drug Channels

SEPTEMBER 13, 2022

By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation.

Biosimilars 97

Biosimilars Pharmacy Hospitals Marketing 97

Drug Channels

OCTOBER 14, 2022

Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. Read on for Steve’s insights. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharma Companies Marketing Research 98

Drug Channels

OCTOBER 25, 2022

Sink your fangs into Amgen’s fantastic new report on the biosimilar boom Wicked! Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Mark Cuban tells ghost stories about PBMs. Walgreens terrifies Wall Street with its 340B losses. Physicians think payers cast evil utilization management spells. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Drugs Pharmacy 98

Drug Discovery World

AUGUST 22, 2022

DDW is delighted to announce that Adam Prosho, Global ILS Training Director, CBRE, will be taking part the Tech Theatre at ELRIG’s Drug Discovery 2022. . How can automation push the development of biologics and biosimilars? . Adam Prosho, Global ILS Training Director, CBRE. The Remote Lab: Is This the Future?

Biosimilars 130

Biosimilars Laboratories Pharmaceutical Companies Drugs 130

Drug Channels

JANUARY 28, 2022

Fiza discusses the impending influx of biosimilars and its effect on manufacturers, specifically in the immunology space. To learn more, sign up for MMIT’s Immunology Biosimilars webcast. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Marketing Drugs 98

Drug Channels

MARCH 31, 2022

Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa. CVS Health takes the red pill. to 1:30 p.m.

Biosimilars 98

Biosimilars Pharmacy Drugs 98

Drug Channels

APRIL 20, 2022

Click here to see the original post and comments from January 2022. For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Channels

JANUARY 19, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Each exclusion list contains 400 to 500 products.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Channels

FEBRUARY 28, 2023

In this issue: Mark Cuban explains his anti-PBM strategy What physicians think about Humira biosimilars States go after PBMs HHS is confused about 340B transparency Plus, The Onion tests your knowledge of United Healthcare’s policies. No promises about future articles. See our forecast to the right.)

Biosimilars 97

Biosimilars Drugs 97

Drug Discovery World

OCTOBER 3, 2022

A series of short seminars focused on automation and technology will be available to visitors at Drug Discovery 2022 which takes place at the ExCel, London 4 and 5 October. Also on that day the Tech Theatre will run a presentation on How automation can push the discovery of biologics and biosimilars?

Laboratories 130

Laboratories Drugs Science Small Molecule 130

Agency IQ

APRIL 26, 2024

Updated guidance on promotional labeling for biosimilars and interchangeables emphasizes a similar approach Today, the FDA issued a revised draft guidance on the development of promotional labeling for biosimilars, reference products, and—newly—interchangeable products. regarding its administration, preparation, storage, or safety).

Biosimilars 40

Biosimilars Science FDA Licensing 40

Drug Channels

APRIL 19, 2022

An ironic postcript: Less than two months after my article was published, Cigna CEO David Cordani bragged about the cost savings from "aggressive adoption" of biosimilars. Anyone want to tell him about the Express Scripts formulary for insulin biosimilars? Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Biosimilars 98

Biosimilars Production FDA Drugs 98

Drug Channels

OCTOBER 11, 2022

I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Drug Distribution Industry Expands as COVID-19 Disruption Fades and Biosimilars Boom (press release) We’re offering special discounted pricing if you order before October 21, 2022!

Pharmaceuticals 74

Pharmaceuticals Biosimilars Licensing Licensing 74

Drug Channels

FEBRUARY 22, 2022

On March 15, 2022, Drug Channels Institute will release The 2022 Economic Report on U.S. We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2022 edition at special discounted prices. Special preorder and launch pricing discounts will be valid through March 28, 2022.

Pharmacy 96

Pharmacy Specialty Pharmacies Biosimilars Licensing 96

FDA Law Blog: Biosimilars

APRIL 25, 2024

This Revised Draft Guidance provides considerations for manufacturers, packers or distributors (dubbed “firms”) of prescription biological reference products, biosimilar products, and interchangeable biosimilar products presenting data and information about such products in promotional materials in a truthful and non-misleading way.

Biosimilars 59

Biosimilars Production FDA Licensing 59

Drug Channels

NOVEMBER 15, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2022. The Outlook 2022 marks our third annual outlook webinar. Broadcast live on December 17, 2021. to 1:30 p.m.

Specialty Pharmacies 94

Specialty Pharmacies Biosimilars Pharmacy Drugs 94

Agency IQ

AUGUST 25, 2023

New FDA guidance on interchangeable biosimilar labeling heads to White House for review The FDA has submitted a draft guidance focused on the labeling of interchangeable biosimilar products to the White House for review, which would fulfill a Biosimilar User Fee Act (BsUFA III) commitment.

Biosimilars 40

Biosimilars FDA Production Licensing 40

The Pharma Data

MARCH 22, 2023

As one of the first adalimumab high-concentration formulation biosimilars approved in the US, Hyrimoz HCF has the potential to expand access for millions of people who face the realities of living with a serious inflammatory disease and to enhance the patient experience,” said Keren Haruvi, President, Sandoz Inc., Head of North America. “As

Biosimilars 40

Biosimilars FDA Approval FDA Pharmacokinetics 40

FDA Law Blog: Biosimilars

JANUARY 11, 2024

The FIE determination released in fall 2023 involves the Reference Product AbbVie’s Humira (adalimumab) and two interchangeable biosimilars—first approved is Cyltezo (adalimumab-adbm), filed by Boehringer Ingelheim Pharmaceuticals, Inc, which was followed by Abrilada (adalimumab-afzb), filed by Pfizer.

Biosimilars 59

Biosimilars FDA Production Packaging 59

Drug Channels

FEBRUARY 21, 2024

Like many of you, I have believed that the Inflation Reduction Act of 2022 (IRA) will encourage Medicare Part D plans to adopt low-list-price products over their high-list/high-rebate counterparts, thereby popping the gross-to-net bubble. Just another IRA-inflicted hit for biosimilars? Actually, maybe not.

Biosimilars 98

Biosimilars Drugs Government Production 98

Drug Channels

AUGUST 25, 2021

Time to pack away the bathing suit and get serious again—with these curated curiosities combed from the now-barren Drug Channels beach: OptumRx joins the PBM GPO game Pharmacy DIR fees hit $11 billion A terrific resource on state biosimilar laws Patient views on utilization management Plus, my social media success…from a (print) newspaper ad!

Biosimilars 83

Biosimilars Pharmacy Drugs Research 83

Drug Discovery World

FEBRUARY 20, 2024

The new report says the anticipated growth to 2028 will be fuelled by the expansion of precision medicine, advancements in drug-drug interaction prediction, analysis of patient-derived data, development of biosimilars, and the increasing number of drug candidates.

Marketing 130

Marketing Biosimilars Drugs Science 130

FDA Law Blog: Biosimilars

JULY 18, 2023

Consistent with that initiative, OPQ recently issued its 2022 Annual Report on the State of Pharmaceutical Quality. Here’s a breakdown of some of the more interesting highlights, statistics and graphics from the FY 2022 report. Recalls Recalls hit a five-year peak in 2022. The PHE also had a dramatic effect on import alerts.

FDA 52

FDA Licensing Licensing Laboratories 52

Drug Channels

MARCH 5, 2024

WHAT YOU WILL LEARN In 2023, the Inflation Reduction Act of 2022 (IRA) began to alter the Medicare Part D program and trigger changes in beneficiary out-of-pocket spending, drug prices, pharmacy economics, and market access strategies. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98

Drug Channels

APRIL 29, 2024

April is over, so it's time to hop into this month’s selection of noteworthy news: CVS Health’s formulary boosts a Humira biosimilar An insurer ditches buy-and-bill to save money for plans—but maybe not for patients?

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Drugs 98

Drug Discovery World

FEBRUARY 22, 2024

trillion on 31 December 2022 to $3.67 Regeneron’s market capitalisation growth was attributed to the FDA approval of its high-dose Eylea – a VEGF fusion protein – for eye diseases, which may likely offset standard Eylea’s expected sales decline following looming biosimilar competition. Nonetheless, there was a resilient upturn of 1.6%

Marketing 130

Marketing FDA Approval Biosimilars FDA 130

Drug Hunter

APRIL 24, 2023

On August 16 th , President Biden signed the $700 billion Inflation Reduction Act of 2022 into law, which includes reforms covering a wide variety of areas including climate change, healthcare, and taxation. Here, commercial reviewer Anthony Vaganos , helps explain what’s in the act and how it impacts drug hunters. For perspective, 4.1

Small Molecule 130

Small Molecule Biosimilars Drugs Vaccine 130

Drug Channels

NOVEMBER 9, 2022

Friday, December 16, 2022 12:00 p.m. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2023. to 1:30 p.m. Read on for full details on pricing and registration.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Drugs 98

Drug Channels

OCTOBER 17, 2022

December 12-14, 2022 in Philadelphia, PA www.informaconnect.com/trade. Don’t miss Informa Connect's Trade & Channel Strategies Summit , coming up December 12-14, 2022 in Philadelphia! Drug Channels readers will save 10% off when they use code 22DRCH10 and register prior to November 11, 2022.*. Other restrictions may apply.

Biosimilars 75

Biosimilars Pharmacy Therapies Production 75

The Pharma Data

JUNE 2, 2022

BYOOVIZ™ is the first FDA approved ophthalmology biosimilar BYOOVIZ, priced 40% lower than LUCENTIS®, provides an equally effective and more affordable treatment option to patients suffering from retinal disorders BYOOVIZ will be commercially available through major distributors across the U.S. on July 1, 2022. Biogen Inc.

Biosimilars 52

Biosimilars FDA Approval Treatment Therapies 52

Drug Channels

NOVEMBER 29, 2022

Please join me for my upcoming live video webinar, Drug Channels Outlook 2023 , on December 16, 2022, from 12:00 p.m. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. If you haven't quit Twitter, you can also find my daily posts at @DrugChannels on Twitter , where I have more than 15,500 followers. to 1:30 p.m.

Pharmacy 97

Pharmacy Drugs Marketing Biosimilars 97

Agency IQ

OCTOBER 20, 2023

BsUFA III regulatory science pilot offers progress report, fields stakeholder criticisms and questions This week, FDA and its grantees briefed stakeholders on the status of research projects funded through the Biosimilar User Fee Act (BSUFA III) Regulatory Science Pilot Program. Developing biosimilars is an extensive and expensive process.

Science 40

Science Biosimilars FDA Production 40